Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus?

Exelixis (EXEL) is drawing attention after a year of strong share performance. The stock is up about 51% over the past 12 months and roughly 171% over three years. Recent trading in Exelixis has been relatively steady, with the share price at US$58.44 and short term moves broadly flat. However, the 1 year total shareholder return of 51.24% and 3 year total shareholder return of 171.81% indicate momentum that has built over time rather than faded. Scan other oncology and biotech players...